Navigation Links
Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
Date:2/2/2010

Adaptive trial design is a hot topic in the drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. In Medelis' new issue of Peer Perspectives in Oncology, Dr. Ranganath Nayak of Cytel Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about its application in phase I and phase II clinical studies.

Phoenix AZ (PRWEB) February 2, 2010 -- Adaptive trial design is a hot topic in the drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. In Medelis' new issue of Peer Perspectives in Oncology, Dr. Ranganath Nayak of Cytel Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about its application in phase I and phase II clinical studies.

"When the industry started seriously talking about adaptive trial design a few years back, the focus was on phase III and seamless phase II/III trials," explains Medelis CEO Bob Bosserman. "But it turns out that the real action today is in phase II dose-finding trials and even in phase I trials for safety.

"Cytel has designed more adaptive trials for industry sponsors than any other service provider and in virtually every therapeutic area," he continued. "Sponsors should carefully consider the adaptive model for the many commercial, ethical, and budgetary benefits that the paper explores."

In the interview, Dr. Nayak, the CEO of Cytel, explains why adaptive trial design is gaining so much momentum in early stage studies. "First, adaptive trials are most helpful when you do not know enough at the beginning of a trial to design it with confidence," he says. "This is much more likely to be true in phases I and II than in phase III.

"Second, the best way to make expensive phase III trials more successful is to do more thorough work in phases I and II," he continues. "Getting the dose right through well-designed phase I and phase II trials is the best way to maximize success in phase III, which then leads to a higher rate of NDAs.

Dr. Nayak offers insight and expertise on a variety of issues surrounding adaptive trial design, including:

 
  • Commercial, ethical, and budgetary benefits of the adaptive trial model;
  • Statistical and data issues;
  • Changing to the adaptive model across multiple sites;
  • Safety issues to consider;
  • Budgeting for an adaptive trial;
  • Dealing with independent decision-making bodies;
  • Patient consent and communication issues;
  • Medical supply logistics;
  • Other best practices and planning issues.

The abstract is free and available for download at Medelis.com.

ABOUT "INSIDER ABSTRACTS"

This abstract is the sixth in Medelis' complimentary "Peer Perspectives in Oncology" Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today: rising costs, optimum patient accrual, targeted therapeutics, patient safety, FDA regulations, efficacy, budgets, and timelines. Previous issues include "Context of Vulnerability," "The Lost Opportunity in Phase I Oncology Trials," "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster," "The Complete Phase IB," and "Patient Safety in Clinical Trials."

These free abstracts are available for download at http://www.medelis.com.

ABOUT CYTEL

Cytel, Inc., is a leading provider of clinical trial services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel has designed more adaptive trials for industry sponsors than any other service provider and in virtually every therapeutic area, helping pharmaceutical and biotech companies raise trial success rates while reducing development time and costs. The methods developed at Cytel are validated and published, with their authors regularly invited speakers on a range of adaptive topics including advances in Bayesian and Frequentist methods, adaptive trial modeling and simulation, key operational areas such as flexible randomization, forecasting of recruitment, and drug supply management. Cytel experts also periodically provide training to FDA biostatisticians on the use of Cytel's software.

ABOUT MEDELIS

Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, team physicians and clinical trial management physicians, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials.

Medelis is privately-held with US locations in Phoenix (headquarters), Nashville, Boston and Reno. Medelis Europe is headquartered in Port Vendres, France.

###

Read the full story at http://www.prweb.com/releases/cro/phaseI-phaseII/prweb3540304.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
2. Siemens Expands the SOMATOM Definition(TM) Line With Worlds First Adaptive CT Scanner
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 
(Date:2/4/2016)... ... February 04, 2016 , ... Franz Inc. ... Graph Database technology has been recognized As “ Best in Semantic Web Technology ... , “At Corporate America, it’s our priority to showcase prominent professionals who are ...
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... COPENHAGEN, Denmark , Feb. 3, 2016 ... stage biotechnology company that applies its innovative TransCon technology ... to present at an upcoming investor conference.Event:2016 Leerink Partners ... York, NY Date:  , Wednesday, February 10, 2016 Time:  ... --> www.ascendispharma.com . --> An audio ...
(Date:2/3/2016)... Denver, Colorado (PRWEB) , ... February 03, 2016 ... ... to hospitals, has established a new office dedicated to the North American healthcare ... provide turnkey solutions to healthcare facilities. The company will provide new pneumatic ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):